Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, L.F-G. Payen, Marie Laugié, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fuméry
Topics & Concepts
MedicineInfliximabInflammatory bowel diseaseInflammatory Bowel DiseasesInternal medicineGastroenterologyTumor necrosis factor alphaDiseaseInflammatory Bowel DiseaseBiosimilars and Bioanalytical MethodsRheumatoid Arthritis Research and Therapies